The incidence of cutaneous squamous cell carcinoma (cSCC) is growing in the United States and epidemiologic data are likely to have underestimated the burden of the disease. New therapies are emerging for the management of advanced/unresectable cSCC that have the potential to alter outcomes. Clinicians need to be made aware of these new options and how they can be integrated into clinical practice. Dermatologists and Mohs surgeons will need to identify patients who are not surgical candidates and engage a multidisciplinary team to discuss systemic options, such as immunotherapy and optimal management approaches.
To address the challenges facing clinicians in the appropriate alignment of treatment to patient, a 3-activity curriculum was developed. This curriculum was hosted online for one year, and findings from this education will be used to develop future content.
